Therapeutic Strategies for the Converging TB/T2DM/HIV Epidemics (R21)

Archived

National Institutes of Health

Description

The purpose of this funding opportunity announcement (FOA) is to invite applications to support innovative research to improve our understanding of innate and adaptive immune dysregulation caused by Type 2 diabetes mellitus (DM) and pre-diabetes that causes increased risk of latent tuberculosis (TB) re-activation and more severe active TB disease with more frequent treatment failure/relapse and death in the context of HIV co-infection.

Who can apply

  • State governments
  • County governments
  • City or township governments
  • Special district governments
  • Independent school districts
  • Public and State controlled institutions of higher education
  • Native American tribal governments (Federally recognized)
  • Public housing authorities / Indian housing authorities
  • Native American tribal organizations (other than Federally recognized)
  • Nonprofits with 501(c)(3) status (other than higher education)
  • Nonprofits without 501(c)(3) status (other than higher education)
  • Private institutions of higher education
  • For-profit organizations other than small businesses
  • Small businesses
  • Others

Contact

NIH OER Webmaster<br/>FBOWebmaster@OD.NIH.GOV<br/>
FBOWebmaster@OD.NIH.GOV

Key dates & funding
  • PostedMay 12, 2017
  • ClosesSep 7, 2020
  • Award ceiling$200,000
  • CFDA93.855, 93.856
Categories

Pro insight

Edit and export this grant’s proposal template, plus deadline reminders, similar-grant suggestions, and funder history — all available with Pro.

Unlock with Pro